Efficacy and safety of jakinibs in rheumatoid arthritis: a systematic review and meta-analysis
- 14 May 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 40 (10), 3989-4005
- https://doi.org/10.1007/s10067-021-05686-8
Abstract
Objectives To assess the efficacy and safety of jakinibs for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response or intolerance to conventional synthetic or biologic disease-modifying antirheumatic drugs (DMARDs). Methods A systematic search was conducted in PubMed, Embase, and the Cochrane Library. Randomized placebo-controlled trials (RCTs) of jakinibs in RA patients were eligible. The effective outcome was RA improvement to reach an American College of Rheumatology 20%/50%/70% (ACR20/50/70) response rate at weeks 12 and 24 after treatment. The safety outcomes included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and discontinuations due to adverse events, infections, and serious infections. Results Twenty-eight randomized, double-blind, controlled trials including 14,500 patients were included. At both weeks 12 and 24, the pooled analysis suggested effective treatment with jakinibs, represented as an increased clinical response of ACR20, ACR50, and ACR70. Subgroup analysis based on different types of jakinibs demonstrated that only peficitinib treatment had no impact on the clinical response of ACR50 or ACR70 at week 12. Jakinibs were associated with an increased incidence of infections at week 12 and TEAEs and infections at week 24. No increase in the risk of SAEs, discontinuations due to adverse events, or serious infections was observed in comparisons between treatment with jakinibs and treatment with placebo in these patients. Conclusions Jakinibs are efficacious and well tolerated in RA patients up to 24 weeks, although they are associated with an increased risk of infectious complications. Key Points • ACR20/50/70 in patients treated with jakinibs was significantly higher than those in patients treated with placebo. • No difference in ACR50/70 was observed in patients with RA treated with peficitinib and placebo. • Jakinibs are beneficial and well tolerated in RA treatment.This publication has 49 references indexed in Scilit:
- Emerging Topical and Systemic JAK Inhibitors in DermatologyFrontiers in Immunology, 2019
- JAK inhibitors for the treatment of autoimmune and inflammatory diseasesAutoimmunity Reviews, 2019
- Diagnosis and Management of Rheumatoid ArthritisJAMA, 2018
- Comparative Price Analysis of Biological Products for Treatment of Rheumatoid ArthritisFrontiers in Pharmacology, 2018
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseasesNature Reviews Drug Discovery, 2017
- Managing rheumatic and musculoskeletal diseases — past, present and futureNature Reviews Rheumatology, 2017
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnnals Of The Rheumatic Diseases, 2017
- Immunopathogenesis of Rheumatoid ArthritisImmunity, 2017
- Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritisNature Biotechnology, 2011
- Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical reviewArthritis Research & Therapy, 2009